Top 20 Bioprinting Companies: Pioneering the Future of Healthcare

The global 3D bioprinting market was valued at roughly 2.69 billion dollars in 2024 and is projected to grow from about 2.97 billion in 2025 to 6.55 billion by 2033, expanding at just over 10 percent annually. Behind those numbers sits an industry attempting something genuinely difficult: using additive manufacturing to build living tissue from human cells, layer by layer, with the eventual ambition of addressing the shortage of transplantable organs.

The field has developed more slowly than early forecasts predicted. Ambitious projections made a decade ago for 2024 and 2025 have not materialized, and printing a fully functional transplantable organ remains out of reach. What has advanced substantially is the commercial infrastructure around bioprinting: reliable desktop bioprinters, standardized bioinks formulated for specific tissue types, and printed tissue models used in drug discovery, toxicology testing, and disease research.

That practical application is where most bioprinting companies actually generate revenue today. Pharmaceutical companies use printed liver and cardiac tissue to test drug toxicity without animal models, cosmetics companies use printed skin for product safety testing, and academic researchers use bioprinters to study tissue development and disease progression.

Comparison Table of Leading Bioprinting Companies

In-Depth Profiles of Leading Bioprinting Companies

CELLINK (BICO Group)

CELLINK, headquartered in Gothenburg, Sweden, and founded in 2016, has established itself as the most widely recognized name in commercial bioprinting. The company specializes in bioprinting solutions and bioinks for the life sciences industry, providing the hardware and materials that allow researchers to create living tissue constructs in laboratory settings.

The company’s Bio X 3D printer has been used in notable research applications, including work at Rensselaer Polytechnic Institute that bioprinted hair follicles within lab-grown human skin tissue. Engineered tissues in that research maintained viability for roughly two to three weeks, a constraint that limited hair shaft development and illustrates the tissue longevity challenges still facing the broader field.

Operating under the BICO Group umbrella, CELLINK combines robotics, artificial intelligence, computer science, and bioprinting to serve medical, pharmaceutical, and cosmetic industry researchers. The company’s stated mission centers on reducing organ shortages and accelerating drug development by making high-quality bioprinting accessible to the broader scientific community rather than restricting it to well-funded institutions.

Organovo

Organovo, founded in 2007 and based in San Diego, was among the earliest companies to demonstrate functional bioprinted tissue. In 2014, the company announced successful printing of liver tissue that functioned comparably to real liver tissue for a period of weeks, and the following year it generated fully functional human kidney tubular tissues using its bioprinting platform.

The company also partnered with L’Oréal to advance development of synthetic skin, reflecting the commercial pull from cosmetics manufacturers seeking alternatives to animal testing for product safety evaluation. This application represents one of the more immediately viable commercial uses for bioprinted tissue, since skin models require less structural complexity than solid organs.

Organovo’s early leadership positioned it as the reference point against which later bioprinting companies were measured, though the timeline for bringing bioprinted products through regulatory approval proved substantially longer than the company’s early projections anticipated. The gap between demonstrated laboratory capability and approved clinical products remains the defining challenge across this entire industry.

Allevi (3D Systems)

Allevi manufactures industrial-grade desktop 3D bioprinters and materials, with its Allevi2 and Allevi 6 models widely adopted across research institutions. The Allevi2 prints living tissue from human cells using a dual extruder system with precision down to 10 microns, giving researchers fine control over construct geometry.

Following its acquisition by 3D Systems, Allevi experienced a reported 19 percent boost in research and development throughput, benefiting from the larger company’s engineering resources. Analysts have noted that Allevi’s compact desktop footprint allowed it to capture roughly 31 percent of the North American educational market, making it the dominant choice for university teaching and research labs.

Allevi represents what analysts have described as the successful democratization of bioprinting, offering a strong utility-to-cost ratio compared with larger and more expensive systems. Excellent cross-platform compatibility and desktop affordability make the company’s printers accessible to research groups that could not justify the cost of enterprise-scale bioprinting installations.

Aspect Biosystems

Aspect Biosystems, founded in 2013 in Vancouver by Tamer Mohamed, Konrad Walus, Sam Wadsworth, and Simon Beyer, has focused on replicating human tissues using microfluidic bioprinting technology. This approach differs meaningfully from standard extrusion printing by controlling cell and material deposition through microfluidic channels rather than simple nozzle extrusion.

The company has oriented itself more toward therapeutic applications than laboratory research tools, pursuing bioprinted tissue implants intended for eventual clinical use rather than focusing primarily on selling printers to research institutions. This therapeutic orientation places Aspect Biosystems on a longer development timeline with correspondingly higher potential impact.

As a leading Canadian entry in a field dominated by European and American companies, Aspect Biosystems has attracted significant attention for its technology platform and its partnerships with pharmaceutical organizations. The company’s focus on tissue therapeutics rather than research hardware distinguishes it from most competitors profiled in this comparison.

3D Systems

3D Systems, one of the founding companies of the broader additive manufacturing industry, announced plans in January 2021 to substantially increase its efforts in regenerative medicine and bioprinting solutions. The company subsequently acquired Allevi, adding established bioprinting hardware and an installed research base to its portfolio.

In September 2022, 3D Systems created Systemic Bio, a dedicated biotech subsidiary aimed at accelerating drug discovery and development through bioprinted tissue models. This structure separates the specialized biological work from the parent company’s broader industrial additive manufacturing operations while retaining access to its engineering and manufacturing capabilities.

The company’s scale and manufacturing expertise give its bioprinting efforts resources that smaller specialized startups cannot match, particularly around production engineering and quality systems. Whether that industrial capability translates into biological breakthroughs remains an open question, since the constraints in bioprinting are more often biological than mechanical.

Stratasys

Stratasys has long been a leader in polymer 3D printing, and the company has increased its focus on the bioprinting sector through a strategic partnership with CollPlant Biotechnologies. That collaboration pairs Stratasys’ printing hardware expertise with CollPlant’s plant-derived recombinant collagen, one of the more promising bioink materials available commercially.

The partnership model reflects a broader pattern in bioprinting, where hardware companies and biomaterials companies combine capabilities rather than each attempting to master both domains. Printing technology and bioink chemistry require genuinely different scientific expertise, and partnerships allow each company to focus on its strength.

Stratasys also maintains a substantial business in medical models and anatomical printing, producing patient-specific physical models used for surgical planning and medical education. This non-cellular medical printing generates revenue today while the company’s bioprinting collaborations pursue longer-term tissue engineering applications.

Cyfuse Biomedical

Cyfuse Biomedical, based in Tokyo, develops 3D tissue engineering technology built around a scaffold-free approach that distinguishes it from most extrusion-based competitors. The company’s flagship Regenova bioprinter manufactures 3D tissues and organs by assembling cell spheroids rather than extruding cells suspended in a supporting bioink matrix.

The company’s Spike device automatically assembles spheroids into desired three-dimensional shapes, and this robotic assembly approach supports development of regenerative medicines and drug discovery applications. Scaffold-free construction avoids questions about how supporting materials degrade or interact with cells over time.

Cyfuse Biomedical represents one of the more technically distinctive approaches in the field, and its methodology has attracted interest from researchers who consider scaffold materials a limiting factor in producing tissue that behaves like its natural counterpart. The company remains among the most prominent bioprinting firms operating from Japan.

ROKIT Healthcare

ROKIT Healthcare, based in Seoul, describes itself as a 4D bioprinting and regenerative medicine biotechnology company, committed to pioneering treatments based on 3D bioprinting principles combined with autologous stem cell use to regenerate and restore tissue and organ function. The company has raised substantial funding, reported in the range of 21.7 billion Korean won.

The autologous approach, using a patient’s own cells rather than donor or engineered cell lines, addresses one of the fundamental challenges in regenerative medicine: immune rejection. Tissue constructed from a patient’s own cells avoids the immunosuppression requirements that complicate conventional transplantation.

ROKIT Healthcare has pursued clinical applications more aggressively than many competitors focused primarily on research tools, positioning itself in the therapeutic segment of the bioprinting market. The company’s combination of bioprinting technology and stem cell biology reflects the interdisciplinary nature of serious regenerative medicine development.

Pandorum Technologies

Pandorum Technologies, a Bangalore-based biotechnology company founded in 2011, focuses on tissue engineering and regenerative medicine through a combination of life science and engineering expertise. The company has raised roughly 24.6 million dollars and uses proprietary technology platforms to design and manufacture functional three-dimensional living human tissues.

Its tissue products are intended for medical research, therapeutic applications, and other uses, with particular attention to corneal and liver tissue development. Corneal tissue represents a comparatively tractable target for bioprinting, since the cornea is relatively thin and avascular, avoiding the vascularization challenge that makes thicker tissues so difficult to sustain.

As the most prominent bioprinting company operating from India, Pandorum Technologies demonstrates that meaningful tissue engineering work is occurring well beyond the traditional biotechnology centers of North America and Western Europe. The company’s synergy of life science and engineering competencies reflects the interdisciplinary teams this field requires.

REGENHU

REGENHU, based in Switzerland and founded in 2007, develops bioprinting technologies intended to impact a range of medical fields rather than targeting a single tissue type or application. The company has built modular bioprinting platforms that researchers can configure for different experimental requirements.

Modularity matters substantially in research bioprinting, since laboratories rarely work on a single tissue type across the life of an instrument. A platform that accommodates different printheads, materials, and deposition methods extends its useful life as research priorities shift within a lab.

REGENHU is among the longer-established European bioprinting platform manufacturers, giving it an installed research base and accumulated application knowledge that newer entrants have not yet matched. Research institutions evaluating platform purchases often weigh this track record alongside raw technical specifications.

Inventia Life Science

Inventia Life Science, headquartered in Sydney with operations extending to the United States and United Kingdom, develops digital droplet bioprinting technology aimed at creating three-dimensional cell models at meaningful throughput. The droplet-based approach differs from extrusion printing by depositing discrete volumes rather than continuous filaments.

High-throughput capability addresses a practical constraint in drug screening applications, where testing compound libraries requires producing large numbers of consistent tissue models rather than a small number of highly complex constructs. Consistency across many replicates matters more than architectural sophistication for this use case.

Pharmaceutical researchers and drug discovery organizations needing reproducible three-dimensional cell models at scale represent Inventia Life Science’s clearest market. The company’s focus on screening applications positions it in the near-term commercial segment of bioprinting rather than the longer-horizon therapeutic tissue space.

CTIBiotech

CTIBiotech, founded in 2009 by Colin McGuckin and based near Lyon, France, develops 3D bioprinting technology with particular emphasis on skin models and immune system research. The company’s skin tissue work serves the cosmetics and dermatology industries, where printed human skin provides an alternative to animal testing for product safety evaluation.

Immune-competent skin models represent a more sophisticated target than basic skin constructs, incorporating immune cells to study inflammatory responses and sensitization. This capability matters for cosmetic and pharmaceutical safety testing, where the key question is often whether a compound triggers an immune reaction rather than simple cytotoxicity.

European regulatory restrictions on animal testing for cosmetics have created sustained commercial demand for validated alternative testing models, positioning companies like CTIBiotech in a market with clear regulatory drivers. This gives the company a more defined near-term revenue path than firms pursuing transplantable organ development.

TissueLabs

TissueLabs specializes in bioprinting technologies for laboratory settings, offering 3D bioprinters, bioinks, and hydrogels designed for creating artificial tissues. The company’s product range covers both the hardware and the materials a laboratory needs to begin bioprinting work without assembling components from multiple suppliers.

Providing an integrated hardware and materials package lowers the barrier for research groups new to bioprinting, who might otherwise need to independently source and validate bioinks compatible with their chosen printer. Material and hardware compatibility problems are a common source of frustration for laboratories starting bioprinting work.

Research laboratories seeking an accessible entry point into tissue engineering represent TissueLabs’ clearest market. The company’s positioning around laboratory accessibility parallels Allevi’s approach, targeting the broad base of academic and institutional research rather than a small number of large industrial installations.

Brinter

Brinter, based in Finland, provides comprehensive bioprinting solutions and services for pharmaceutical, biotechnology, and cosmetic industries alongside universities and research facilities. The company has raised roughly 2.2 million dollars and built its platform around a modular architecture using interchangeable print tool heads.

The modular tool head design allows a single Brinter system to accommodate different printing methods and materials by swapping components rather than purchasing separate instruments. For laboratories working across multiple tissue types or material systems, this configurability can substantially reduce total equipment investment.

Pharmaceutical and cosmetic industry researchers, alongside academic facilities, form Brinter’s target market. The company’s service component, providing bioprinting expertise alongside hardware, addresses the reality that many organizations purchasing bioprinters lack internal experience operating them effectively.

REGEMAT 3D

REGEMAT 3D, based in Granada, Spain, and founded in 2011, pioneered the use of 3D printing for regenerative therapies with a focus on customizable systems configured to specific research requirements. The company has raised roughly 1.1 million dollars and built a reputation around configurable rather than fixed-function bioprinting platforms.

Cartilage regeneration has been a particular area of focus, representing a tissue type with clearer near-term clinical potential than complex vascularized organs. Cartilage lacks blood vessels in its natural state, which removes the vascularization requirement that constrains thicker tissue constructs.

Research institutions and clinical researchers pursuing regenerative therapy applications represent REGEMAT 3D’s clearest market. The company’s emphasis on customization appeals to research groups whose requirements do not fit standard commercial system configurations.

Advanced Solutions Life Sciences

Advanced Solutions Life Sciences, based in Louisville, Kentucky, develops solutions spanning living organisms, molecular biology, and biotechnology, with its BioAssemblyBot platform built around six-axis robotic bioprinting. The robotic arm architecture allows deposition along paths that fixed-gantry printers cannot achieve.

Six-axis motion matters for building structures with complex internal geometry, particularly vascular networks that require deposition along curved, branching paths rather than the layer-by-layer planar approach standard gantry systems use. Vascularization remains the central obstacle to building thicker functional tissues.

Research organizations working on vascularized tissue constructs and complex three-dimensional architectures represent this company’s clearest market. The robotic approach involves greater mechanical complexity than desktop extrusion systems, positioning BioAssemblyBot toward well-resourced research programs rather than teaching laboratories.

SunP Biotech

SunP Biotech specializes in 3D bioprinting systems, bioinks, and advanced biological models for tissue engineering, cancer research, and drug testing applications. The company’s proprietary technology centers on a screw-based extrusion technique that streamlines the bioprinting process and improves efficiency in biomedical research.

Screw-based extrusion provides more consistent material flow than pneumatic systems, particularly with viscous bioinks that resist smooth pressure-driven deposition. Flow consistency directly affects construct quality, since variation in deposition rate produces uneven cell density across a printed structure.

Cancer research applications represent a significant use case for SunP Biotech’s technology, since three-dimensional tumor models better replicate how cancer cells behave in the body than flat two-dimensional cultures. Drug testing against more realistic tumor models can reveal efficacy and resistance patterns that conventional culture systems miss.

Poietis

Poietis, based in France, leads in laser-assisted bioprinting, a technique offering single-cell resolution that extrusion-based methods cannot match. Laser-assisted deposition transfers individual cells or small cell clusters with precision measured at the scale of individual cells rather than the tens of microns typical of extrusion nozzles.

That resolution advantage matters for applications where precise cellular arrangement determines function, since many tissues depend on specific spatial relationships between different cell types. Extrusion printing mixes cells within a bioink and deposits them together, limiting control over individual cell placement.

The tradeoff is throughput, since depositing cells individually is inherently slower than extruding a continuous cell-laden filament. Research applications requiring precise cellular architecture rather than bulk tissue volume represent the clearest fit for laser-assisted bioprinting technology.

CollPlant Biotechnologies

CollPlant Biotechnologies, based in Israel, produces plant-derived recombinant human collagen, addressing one of the most persistent material challenges in bioprinting. Collagen is the primary structural protein in human tissue, but animal-derived collagen carries immunogenicity and disease transmission concerns that complicate clinical translation.

The company’s plant-based production system generates human collagen without animal sourcing, producing a material suited for both bioinks and regenerative implants. This positions CollPlant as a materials supplier serving other bioprinting companies rather than as a direct competitor in hardware.

The strategic partnership with Stratasys pairs CollPlant’s material with established printing hardware expertise, reflecting the complementary relationship between biomaterials science and printing technology. Companies developing bioinks and companies developing printers frequently need each other to bring complete solutions to market.

UPM Biomedicals

UPM Biomedicals, part of Finnish forestry company UPM, develops high-quality nanofibrillar cellulose specifically for 3D bioprinting applications. Deriving biomaterials from wood pulp represents an unusual path into biotechnology, drawing on the parent company’s deep expertise in cellulose chemistry.

Nanofibrillar cellulose forms hydrogels with properties well suited to supporting cells during and after printing, providing structural support without the animal sourcing concerns attached to many conventional biomaterials. The material’s consistency and scalability benefit from industrial-scale cellulose processing infrastructure.

Research laboratories and companies needing reliable, consistently manufactured hydrogel materials for cell culture and bioprinting represent UPM Biomedicals’ clearest market. The company illustrates how established industrial materials expertise can transfer into biotechnology when the underlying chemistry aligns with biological requirements.

Where Bioprinting Goes From Here

The gap between demonstrated capability and clinical reality remains the defining characteristic of this industry. Companies have printed liver tissue that functioned for weeks, kidney tubular structures, and skin containing hair follicles, yet none of these has become an approved clinical therapy. Vascularization stands as the central technical obstacle, since tissue thicker than a few hundred microns requires a blood supply that current printing methods cannot reliably create.

Commercial viability today rests largely on research and testing applications rather than transplantation. Pharmaceutical toxicology testing, cosmetics safety evaluation under regulations restricting animal testing, and cancer research using three-dimensional tumor models all generate revenue now, funding the longer-horizon work toward therapeutic tissue. Companies with both near-term revenue and therapeutic ambitions are generally better positioned than those depending entirely on breakthroughs that remain years away.

Consolidation has already begun reshaping the field, with 3D Systems acquiring Allevi and Stratasys partnering with CollPlant, suggesting that established additive manufacturing companies see bioprinting as a strategic extension rather than a separate industry. Whether the biological problems yield to industrial engineering resources or require fundamentally different scientific advances will likely determine which companies on this list still exist a decade from now.

FAQ

Q: What is 3D bioprinting?

A: Bioprinting uses additive manufacturing techniques to deposit living cells, biomaterials, and supporting structures layer by layer to create tissue constructs. The goal ranges from producing research tissue models to eventually creating transplantable organs.

Q: Can bioprinting create transplantable organs today?

A: No. Despite significant progress, printing a fully functional transplantable organ remains out of reach. Current commercial applications focus on tissue models for research, drug testing, and cosmetics safety evaluation.

Q: What is a bioink?

A: A bioink is the material that carries living cells during printing, typically a hydrogel that provides structural support while allowing cells to survive and function. Materials include plant-derived collagen, alginate, and nanofibrillar cellulose.

Q: How large is the bioprinting market?

A: The global 3D bioprinting market was valued at roughly 2.69 billion dollars in 2024 and is projected to reach about 6.55 billion by 2033, growing at just over 10 percent annually according to industry research.

Q: Why is vascularization such a challenge in bioprinting?

A: Tissue thicker than a few hundred microns requires a blood supply to deliver oxygen and nutrients to interior cells. Creating functional vascular networks within printed constructs remains the central technical obstacle to building thicker tissues.

Q: What are bioprinted tissues used for commercially today?

A: Current applications include pharmaceutical toxicology testing, cosmetics safety evaluation as an alternative to animal testing, cancer research using three-dimensional tumor models, and academic tissue engineering research.

Q: What is the difference between extrusion and laser-assisted bioprinting?

A: Extrusion bioprinting pushes cell-laden bioink through a nozzle, offering speed and volume. Laser-assisted bioprinting, used by companies like Poietis, deposits cells with single-cell resolution but at lower throughput.

Q: What is scaffold-free bioprinting?

A: Scaffold-free approaches, such as Cyfuse Biomedical’s spheroid assembly method, build tissue from cell aggregates without a supporting biomaterial matrix. This avoids questions about how scaffold materials degrade or interact with cells over time.

Q: Which countries lead in bioprinting development?

A: Sweden, the United States, Canada, Japan, South Korea, France, Switzerland, and India all host significant bioprinting companies, reflecting a genuinely global research and commercial landscape rather than concentration in a single region.

Q: Are bioprinting companies profitable today?

A: Most generate revenue from research hardware, bioinks, and contract tissue model services rather than therapeutic products. Companies pursuing transplantable tissue operate on long development timelines with corresponding financial risk.